Hyperlipidemia, Familial Combined, 3 (FCHL3)

Alias:

Familial Combined Hyperlipidemia

Combined Hyperlipidemia, Familial

Mixed Hyperlipidaemia

Fchl3

Familial Hyperbetalipoproteinaemia and Hyperprebetalipoproteinaemia

Hypercholesterolaemia with Endogenous Hyperglyceridaemia

Hyperbetalipoproteinaemia with Prebetalipoproteinaemia

Hyperbetalipoproteinemia with Prebetalipoproteinemia

Familial Multiple Lipoprotein-Type Hyperlipidemia

Familial Hypercholesterolaemia with Hyperlipaemia

Prebetalipoproteinemia Hyperbetalipoproteinaemia

Hyperlipidemia, Familial Combined, Lpl Related

Hyperlipidemia, Combined, Familial

Hyperlipidemia, Familial Combined

Hyperlipidemia Familial Combined

Type Iib Hyperlipoproteinemia

Hyperlipoproteinemia Type Iib

Remnant Hyperlipoproteinemia

Hyperlipidaemia, Group C

Mixed Hyperlipemia

Favorite

Basic Information

Medical Symptom

Gene & Mutation

Related Drugs

Disease Model

References Literature

Hyperlipidemia, Familial Combined, 3, also known as familial combined hyperlipidemia, is related to hyperlipidemia, familial combined, 1 and hypercholesterolemia, familial, 2. An important gene associated with Hyperlipidemia, Familial Combined, 3 is LPL (Lipoprotein Lipase), and among its related pathways/superpathways are Metabolism and Olfactory Signaling Pathway. The drugs Fenofibrate and Lovastatin have been mentioned in the context of this disorder. Affiliated tissues include heart and liver, and related phenotypes are xanthelasma and myocardial infarction

Related ID：

MALACARDS：HYP838

OMIM：144250

MESH：D006950

ICD11：405028062